What is Pluri?
Pluri Inc. operates at the intersection of advanced biotechnology and industrial scalability. The company specializes in the development of proprietary cell expansion platforms designed to manufacture biological cells for diverse applications. Its core business model focuses on three primary verticals: healthcare, where it contributes to regenerative medicine; food production, through the creation of sustainable protein alternatives; and agriculture. By providing a scalable infrastructure for cell-based technologies, Pluri addresses the growing global demand for efficient, lab-grown biological solutions that bypass traditional resource-intensive production methods. Its market position is defined by its ability to bridge the gap between laboratory-scale innovation and commercial-scale manufacturing.
How much funding has Pluri raised?
Pluri has raised a total of $10M across 2 funding rounds:
Other Financing Round
$6.5M
Other Financing Round
$3.5M
Other Financing Round (2025): $6.5M, investors not publicly disclosed
Other Financing Round (2025): $3.5M led by Merchant Adventure Investment Advisors
Key Investors in Pluri
Merchant Adventure Investment Advisors
A global investment firm that prioritizes knowledge-based companies and management competency, focusing on businesses that deliver significant utility through innovative products and services.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Pluri?
Looking ahead, Pluri is expected to utilize this recent capital to optimize its manufacturing throughput and broaden its intellectual property portfolio. The strategic focus will likely center on scaling its cell expansion technology to meet the rigorous demands of the healthcare and food sectors. As the company continues to refine its operational efficiency, stakeholders anticipate further expansion of its partnership ecosystem, which remains a cornerstone of its growth strategy. By maintaining a focus on high-utility biological products, Pluri is well-positioned to capture significant market share in the burgeoning field of synthetic biology and cellular agriculture, ensuring long-term value creation for its investors and partners alike.
See full Pluri company page
